Search Results

Displaying Results 2051-2075 of 8112 "'III'"

Jun 22, 2026, 03:00 ET Ardagh Group S.A. Commences Excess Proceeds Offer

Promotion Order"), (ii) are persons falling within Article 43(2) ("members and creditors of certain bodies corporate") of the Financial Promotion Order, (iii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Promotion Order,

More news about: Ardagh Group S.A.


Jun 22, 2026, 01:45 ET Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell

induce TROP2 upregulation in DTP cells, providing a mechanistic basis for combining sac-TMT with EGFR-TKI.— The Company is conducting a Phase III registrational study of sac-TMT plus osimertinib as first-line treatment for advanced EGFR-mutant NSCLC (enrollment completed; follow‑up phase) and a

More news about: Kelun-Biotech


Jun 22, 2026, 01:09 ET J-Elephant Received Strategic Investment from Geek+, Expanding Partnership in Pallet Warehouse Automation

systems are purpose-built for high-value industries including manufacturing, pharmaceuticals, food and beverage, and renewable energy.III. Global Expansion: Strengthening Competitiveness in Intelligent RoboticsThrough this partnership, J-Elephant gains immediate access to Geek+'s

More news about: J-Elephant


Jun 22, 2026, 01:00 ET Inspira Enterprise Expands to Full Suite of ServiceNow Platform Capabilities

unexpected difficulties and expenses in executing the product capabilities and offerings, (ii) changes in the regulatory landscape related to AI and (iii) uncertainty as to whether sales will justify the investments in the product capabilities and offerings. Further information on factors that could affect

More news about: Inspira Enterprise


Jun 22, 2026, 01:00 ET Inspira Enterprise Expands to Full Suite of ServiceNow Platform Capabilities

unexpected difficulties and expenses in executing the product capabilities and offerings, (ii) changes in the regulatory landscape related to AI and (iii) uncertainty as to whether sales will justify the investments in the product capabilities and offerings. Further information on factors that could affect

More news about: Inspira Enterprise


Jun 22, 2026, 01:00 ET Inspira Enterprise étend son offre pour couvrir l'ensemble des fonctionnalités de la plateforme ServiceNow

et les dépenses liées à la mise en œuvre des fonctionnalités et des offres du produit, (ii) les évolutions du cadre réglementaire en matière d'IA et (iii) l'incertitude quant à la capacité des ventes à justifier les investissements consentis dans les fonctionnalités et les offres du produit. De plus amples

More news about: Inspira Enterprise


Jun 21, 2026, 20:00 ET Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma

multiple myeloma (R/R MM). IBI3003 is China's first self-developed anti-GPRC5D/BCMA/CD3 tri-specific antibody to enter the pivotal registrational Phase III clinical trial, aiming to bring a promising next-generation immunotherapy option for Chinese R/R MM patients. TriadicMM-1 (NCT07623798) is a multicenter,

More news about: Innovent Biologics


Jun 19, 2026, 22:00 ET Sportradar Securities Fraud Class Action Result of Compliance Misrepresentations and 22% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Sportradar's operations; (ii) the Company's Know-Your-Customer ("KYC") and compliance processes were not as robust as Defendants' had claimed; and (iii) as a result, the Company's statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable

More news about: Kahn Swick & Foti, LLC


Jun 19, 2026, 22:00 ET SES AI Corporation Securities Fraud Class Action Result of Weak Revenue Guidance and 37% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

no operational capacity; (ii) the company created the appearance of revenue by purchasing services tied to its own Molecular Universe transactions; (iii) despite its optimistic growth statements, SES AI faced significant logistics constraints in Q4 2025 that materially impacted revenue for that quarter;

More news about: Kahn Swick & Foti, LLC


Jun 19, 2026, 22:00 ET ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

that: (i) the Company engaged in an undisclosed related party transaction; (ii) the Company used channel stuffing to create an appearance of revenue; (iii) the Company lacked adequate internal controls; (iv) as a result, Defendants' statements about the Company's business, operations, and prospects were

More news about: Kahn Swick & Foti, LLC


Jun 19, 2026, 22:00 ET PicS N.V. Notice of August 4, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

R$590 million of exposures from Stage 2 to Stage 3, resulting in an incremental ECL charge of R$88 million for the quarter ended December 31, 2025; (iii) the Company experienced an undisclosed Stage 3 formation rate exceeding 7% in the fourth quarter of 2025, materially departing from the historical trends

More news about: Kahn Swick & Foti, LLC


Jun 19, 2026, 18:30 ET PICS INVESTOR NOTICE: RGRD Law Files Class Action Lawsuit Against PicS N.V. and Announces Opportunity for Investors with Substantial Losses to Lead Class Action Lawsuit

exposures previously classified as Stage 2 to Stage 3, leading to an incremental ECL charge of R$88 million in the three months ended December 31, 2025; (iii) PicS N.V. had experienced a heightened, but unreported, Stage 3 formation rate of more than 7% in the fourth quarter of 2025 that deviated substantially

More news about: Robbins Geller Rudman & Dowd LLP


Jun 19, 2026, 14:34 ET Texas Southern University and Dr. Ruth J. Simmons Announce Endowment and New Clinic to Support Breast Cancer Prevention and Education

Grimes, Matagorda, Wharton, Trinity and Polk."This is a legacy moment and so much more," said Texas Southern University President J.W. Crawford III. "I am thankful to Dr. Ruth J. Simmons and the Wilson family for the gift to Texas Southern University. More importantly, I am thankful to them for entrusting

More news about: Texas Southern University


Jun 19, 2026, 14:11 ET Texas Southern University's Ocean of Soul Marching Band Featured in Vogue Magazine on Juneteenth

moment."This moment does not just belong to our students and the University, but to Houston and to every HBCU in this country," said J.W. Crawford III, President of Texas Southern University. "To be in Vogue is incredible, and for this to happen on Juneteenth, in the region where Juneteenth began,

More news about: Texas Southern University


Jun 19, 2026, 07:49 ET RGC EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026

manipulation; (ii) the resulting volatility in the market for the Company's ordinary shares exposed Regencell's investors to significant financial risk; (iii) all the foregoing subjected Regencell to a heightened risk of regulatory and/or governmental scrutiny and enforcement action, as well as significant

More news about: Faruqi & Faruqi, LLP


Jun 19, 2026, 07:05 ET /C O R R E C T I O N -- MDA Space/

third-party approvals, and the failure to obtain any such approvals or satisfy any such conditions could delay or prevent the closing of the acquisition; (iii) any projected, estimated or forecasted financial information presented in connection with the acquisition will be achieved, as such projections are

More news about: MDA Space


Jun 19, 2026, 05:00 ET Gelatin Market worth $6.43 billion by 2031- Exclusive Report by MarketsandMarkets™

Marine Collagen Market by Type (Type I, Type III, Other types), Source (Fish Skin, Scales, & Muscles, Fish Bones & Tendons, Other Sources), Marine Animal (Fish, Other Types), Application, Extraction

More news about: MarketsandMarkets


Jun 18, 2026, 23:19 ET THE MARKET HAS SPOKEN: Wants Neugebauer and Fermi Board to Maximize Shareholder Value and Enhance Management

beneficially owns 44,656,376 shares of Common Stock; (ii) 94,359,659 shares of Common Stock beneficially owned by the Melissa A. Neugebauer 2020 Trust; and (iii) 7,500,000 shares of Common Stock underlying restricted stock units held by Mr. Neugebauer that vested in connection with his termination without cause.

More news about: Toby Neugebauer


Jun 18, 2026, 23:08 ET THE MARKET HAS SPOKEN: Wants Neugebauer and Fermi Board to Maximize Shareholder Value and Enhance Management

beneficially owns 44,656,376 shares of Common Stock; (ii) 94,359,659 shares of Common Stock beneficially owned by the Melissa A. Neugebauer 2020 Trust; and (iii) 7,500,000 shares of Common Stock underlying restricted stock units held by Mr. Neugebauer that vested in connection with his termination without cause.

More news about: Toby Neugebauer


Jun 18, 2026, 18:56 ET GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit

since attested, the trial as executed within the three-year follow-up period was insufficient to demonstrate the achievability of a reduction in Stage III-IV cancers; defendants disclosed the trial period, and thus the screening duration, was apparently insufficient to demonstrate whether the primary endpoint

More news about: THE ROSEN LAW FIRM, P. A.


Jun 18, 2026, 17:57 ET ZTS INVESTOR NOTICE: Zoetis Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit

Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (iii) Zoetis' dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment.On August

More news about: Robbins Geller Rudman & Dowd LLP


Jun 18, 2026, 17:50 ET RBLX DEADLINE NOTICE: Roblox Corporation Investors with Substantial Losses Have Opportunity to Lead the Roblox Class Action Lawsuit

while continuing to be "enormously bullish" on their tech rollouts as well as claiming to be able to "rely on [their] tremendous organic growth"; and (iii) Roblox relied far too heavily on viral events to drive growth and failed to communicate to investors the potential knock-on impacts of the age verification

More news about: Robbins Geller Rudman & Dowd LLP


Jun 18, 2026, 16:45 ET Contango Announces Results of the 2026 Virtual Annual Meeting of Stockholders

patented mining claims located in the Willow Mining District about 75 miles north of Anchorage, Alaska, from the underlying owner, Alaska Hardrock Inc., (iii) mineral rights to approximately 145,000 acres of State of Alaska mining claims, (iv) mineral rights to approximately 11,700 acres of State of Alaska

More news about: Contango Silver & Gold Inc.


Jun 18, 2026, 16:10 ET Saul Centers Declares Quarterly Dividends

disruptions, which may lead to a disruption of, or lack of access to, sources of funding and rising inflation, (ii) the ability of our tenants to pay rent, (iii) our reliance on shopping center "anchor" tenants and other significant tenants, (iv) our substantial relationships with members of the B. F. Saul Company

More news about: Saul Centers, Inc.


Jun 18, 2026, 12:31 ET Insomnia Market Witnesses Robust Growth During the Forecast Period (2026-2036) with Emerging Orexin Receptor Antagonists and Melatonin Receptor Agonist | DelveInsight

Drugs Recent Developments in the Insomnia MarketIn September 2025, Johnson & Johnson reported results from the Phase III MDD3005 26-week clinical trial evaluating Seltorexant as an adjunctive treatment in adults and elderly patients with MDD experiencing insomnia symptoms.

More news about: DelveInsight Business Research, LLP


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.